Actively Recruiting
A Prospective Approach for the Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2026-04-09
40
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
N
National Heart, Lung, and Blood Institute (NHLBI)
Lead Sponsor
N
National Institutes of Health Clinical Center (CC)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating ways to detect early signs of lung inflammation and injury in people who have received allogeneic hematopoietic stem cell transplantation (HSCT). This procedure involves receiving stem cells from a donor and is used to treat blood cancers and immune system disorders. The study aims to find better methods to identify lung problems caused by the immune system attacking healthy lung cells after HSCT. Participants will undergo several tests before and regularly for two years after their HSCT. These tests include ultra-low dose CT scans to image the lungs, bronchoscopy with lavage to collect lung cells and fluids while sedated, blood tests every 2 to 4 weeks, and pulmonary function tests including a 6-minute walk test. These assessments will help researchers monitor lung health and detect inflammation early. During the study, participants will have repeated imaging, lung fluid sampling, blood draws, and breathing tests to track lung function and inflammation. The primary goal is to identify lung injury earlier using chest imaging and bronchoscopy. The study will also analyze lung and blood samples to understand the biological changes linked to lung problems after HSCT. The total observation period for participants is 30 months, allowing detailed monitoring of lung health over time.
CONDITIONS
Brief Title
Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to comply with all study procedures and available for the entire study duration
- Male or female, aged 5 to 70 years
- Scheduled to receive allogeneic HSCT for hematologic malignancy, blood, or immune system disorders at the NIH Clinical Center
- Able to understand and willing to sign informed consent
You will not qualify if you...
- Pregnancy or lactation
- For women of reproductive potential, must have a negative serum pregnancy test during screening
- Women of reproductive potential defined as sexually mature women without hysterectomy, bilateral oophorectomy, tubal occlusion, or natural menopause for at least one year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 30 months
Participants undergo sequential chest imaging and bronchoalveolar lavage (BAL) measures to detect early lung injury related to infection or alloreactive syndromes after allogeneic hematopoietic stem cell transplantation (HSCT).
Regular assessments including chest tomography and bronchoscopy with lavage
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
G
Gloria Y Pastor, R.N.
A
Anthony F Suffredini, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here